1. Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model
   Juozas Vasiliauskas et al, 2014, Oncotarget CrossRef
2. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
   Andreas Varkaris et al, 2016, Clinical Cancer Research CrossRef
3. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
   Christoph Burdelski et al, 2017, Oncotarget CrossRef
4. Cabozantinib in genitourinary malignancies
   Tian Zhang et al, 2017, Future Oncology CrossRef
5. Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic
   Denis L.F. Jardim et al, 2014, Clinical Cancer Research CrossRef
6. Met in Urological Cancers
   Yasuyoshi Miyata et al, 2014, Cancers CrossRef
7. In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B
   Janet C. Reid et al, 2016, Biological Chemistry CrossRef
8. Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
   Pengxiao Su et al, 2023, Frontiers in Oncology CrossRef
9. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas
   Aleksandra Paliga et al, 2017, American Journal of Clinical Oncology CrossRef
10. Therapies for Locally Advanced and Metastatic Adrenocortical Carcinoma
    Sarika N. Rao et al, 2017, Management of Adrenal Masses in Children and Adults CrossRef
11. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors
    Denis L.F. Jardim et al, 2015, Clinical Genitourinary Cancer CrossRef